in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a ...

in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a ...

14 data cut, the Brisbane, California-based biotech said amezalpat led to a six-month survival advantage with cancer ... atezolizumab, and bevacizumab in previously untreated patients with ...

Health NZ is pleased to accept an offer from Roche to provide two medicines for people with unresectable hepatocellular carcinoma until the end of February. The medicines, Tecentriq (atezolizumab) and ...

in combination with atezolizumab and bevacizumab in treatment naive patients with unresectable locally advanced or metastatic hepatocellular carcinoma, has been selected for a poster presentation ...

in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a ...

in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a ...